Timing and dose of statin therapy define its impact on inflammatory and endothelial responses during myocardial infarction

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 5, 2011, Pages 1240-1246

  Sposito, Andrei C ^a   Santos, Simone N ^b   De Faria, Eliana Cotta ^a   Abdalla, Dulcineia S P ^c   Da Silva, Luiza P ^a   Soares, Alexandre A Sousa ^a   Japiassú, André V T ^a   Quinaglia E Silva, Jose C ^d   Ramires, Jose A F ^c   Coelho, Otavio Rizzi ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF BRASILIA   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d HOSPITAL DE BASE DO DISTRITO FEDERAL   (Brazil)

Author keywords

acute coronary syndromes; cytokines; endothelial function

Indexed keywords

8 ISOPROSTANE; C REACTIVE PROTEIN; CHOLESTEROL; CREATINE KINASE MB; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 2; LOW DENSITY LIPOPROTEIN; NITRATE; NITRITE; SIMVASTATIN; TROPONIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD VESSEL REACTIVITY; BRACHIAL ARTERY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG POTENCY; FEMALE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART MUSCLE NECROSIS; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT DURATION; TREATMENT RESPONSE; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 85027938156     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.218685     Document Type: Article

References (18)

1. Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol. 2002;22:1524-1534.
2. Morrissey RP, Diamond GA, Kaul S. Statins in acute coronary syndromes: do the guideline recommendations match the evidence? J Am Coll Cardiol. 2009;54:1425-1433.
3. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res. 2004;94:1543-1553. (Pubitemid 38856961)
4. Anzai T, Yoshikawa T, Shiraki H, Asakura Y, Akaishi M, Mitamura H, Ogawa S. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation. 1997; 96:778-784. (Pubitemid 27329609)
5. Pietila KO, Harmoinen AP, Jokiniitty J, Pasternack AI. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J. 1996;17:1345-1349. (Pubitemid 26306662)
6. Correia L, Sposito A, Passos L, Lima J, Braga J, Rocha M, Esteves J, D'Oliveira A Jr. Short-term effect of atorvastatin (80 mg) on plasma lipids of patients with unstable angina pectoris or non-Q wave acute myocardial infarction. Am J Cardiol. 2002;90:162-164. (Pubitemid 34775128)
7. Correia LC, Sposito AC, Lima JC, Magalhaes LP, Passos LC, Rocha MS, D'Oliveira A, Esteves JP. Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction. Am J Cardiol. 2003;92:298-301. (Pubitemid 36897715)
8. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med. 2001;134:657-662. (Pubitemid 32322244)
9. Damasceno NR, Sevanian A, Apolinario E, Oliveira JM, Fernandes I, Abdalla DS. Detection of electronegative low density lipoprotein (LDL-) in plasma and atherosclerotic lesions by monoclonal antibody-based immunoassays. Clin Biochem. 2006;39:28-38. (Pubitemid 43005267)
10. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002;53:31-47. (Pubitemid 34020764)
11. Fichtlscherer S, Breuer S, Zeiher AM. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: further evidence for the existence of the "vulnerable" patient. Circulation. 2004;110:1926-1932. (Pubitemid 39331903)
12. Uren NG, Crake T, Lefroy DC, de Silva R, Davies GJ, Maseri A. Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction. N Engl J Med. 1994;331:222-227. (Pubitemid 24226679)
13. Bhagat K. Endothelial function and myocardial infarction. Cardiovasc Res. 1998;39:312-317. (Pubitemid 28346527)
14. Vita JA, Keaney JF Jr, Larson MG, Keyes MJ, Massaro JM, Lipinska I, Lehman BT, Fan S, Osypiuk E, Wilson PW, Vasan RS, Mitchell GF, Benjamin EJ. Brachial artery vasodilator function and systemic inflammation in the Framingham Offspring Study. Circulation. 2004;110: 3604-3609. (Pubitemid 39612578)
15. Wang X, Guo F, Li G, Cao Y, Fu H. Prognostic role of brachial reactivity in patients with ST myocardial infarction after percutaneous coronary intervention. Coron Artery Dis. 2009;20:467-472.
16. Dupuis J, Tardif JC, Rouleau JL, Ricci J, Arnold M, Lonn E, Roux R, Title LM, Amyot R, Bonafede N, Woo A, Cannon CP. Intensity of lipid lowering with statins and brachial artery vascular endothelium reactivity after acute coronary syndromes (from the BRAVER trial). Am J Cardiol. 2005;96:1207-1213. (Pubitemid 41505394)
17. Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial. Circulation. 1999;99:3227-3233. (Pubitemid 29293431)
18. Lenderink T, Boersma E, Gitt AK, Zeymer U, Wallentin L, Van de Werf F, Hasdai D, Behar S, Simoons ML. Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than non-users: a report from the first Euro Heart Survey on acute coronary syndromes. Eur Heart J. 2006;27:1799-1804. (Pubitemid 44297384)